Under the deal, which has already been approved unanimously by both companies’ boards, Sanofi will gain Kadmon’s drug Rezurock, which was approved in July to treat chronic graft-versus-host disease in both adults and adolescents.
Kadmon focuses on developing drugs for diseases with significant unmet medical needs.
“By leveraging Sanofi’s global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster,” Harlan Waksal, MD, Kadmon’s president and CEO said in a news release.
Sanofi said it expects the deal to close in the fourth quarter of this year.
Read the full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
